RxDoctor Payments Data

Sammita Satyanarayan, MD

Neurology · New York, NYNPI 1639531882

Payments from drug & device makers

$78,730in general payments, 2019–2025

Across 8 payments — averaging $9841.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$73K
  • EMD Serono, Inc.$3K
  • TG Therapeutics, Inc.$3K
  • AstraZeneca$45
$3,375in research payments, 2019–2025

Across 1 payment — averaging $3375.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • TG Therapeutics, Inc.$3K

What the payments were for

  • Consulting fees$5,70094%
  • Food & beverage$3376%

General payments by program year

22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)2$72,808
EMD Serono, Inc.4$3,176
TG Therapeutics, Inc.1$2,700
AstraZeneca1$45

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$78,730 in reported general payments places this provider in the 85th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$16,661
Medicare patients
65
Services billed
154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TecfideraDimethyl Fumarate21$184,515
Dimethyl Fumarate12$53,927
Glatiramer Acetate13$38,060
Dalfampridine ErDalfampridine14$1,391
Baclofen32$493
Gabapentin33$136
Tizanidine Hcl11$72

Paid to pharmacies, not to this prescriber.

Other neurology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →